Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- Conditions
- Advanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Fallopian Tube CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell CarcinomaOvarian CarcinomaPathologic Stage III Cutaneous Melanoma AJCC V8
- Interventions
- Drug: CarboplatinDrug: EribulinDrug: FluorouracilDrug: PaclitaxelDrug: CyclophosphamideDrug: CapecitabineBiological: PembrolizumabDrug: OlaparibBiological: NivolumabBiological: IpilimumabDrug: SelinexorDrug: DoxorubicinDrug: TopotecanDrug: PemetrexedDrug: Irinotecan HydrochlorideDrug: OxaliplatinDrug: Leucovorin Calcium
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 221
- Registration Number
- NCT02419495
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 96
- Registration Number
- NCT02408861
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States
Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- Radiotherapie
- Target Recruit Count
- 13
- Registration Number
- NCT02406183
- Locations
- 🇧🇪
Dept. of Radiotherapy, Ghent University Hospital, Ghent, Oost-Vlaanderen, Belgium
Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 10
- Registration Number
- NCT02403778
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Bilineal LeukemiaRefractory Acute Myeloid LeukemiaAcute Biphenotypic LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaSecondary Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT02397720
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 906
- Registration Number
- NCT02388906
- Locations
- 🇺🇸
Local Institution - 0157, Columbus, Ohio, United States
🇺🇸Local Institution - 0013, Boston, Massachusetts, United States
🇺🇸Local Institution - 0025, Durham, North Carolina, United States
A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma
- First Posted Date
- 2015-03-11
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- Craig L Slingluff, Jr
- Target Recruit Count
- 3
- Registration Number
- NCT02385669
- Locations
- 🇺🇸
Cancer Center at the University of Virginia, Charlottesville, Virginia, United States
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2015-02-27
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Melanoma Institute Australia
- Target Recruit Count
- 76
- Registration Number
- NCT02374242
- Locations
- 🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
🇦🇺Melanoma Institute Australia, North Sydney, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 600
- Registration Number
- NCT02339571
- Locations
- 🇺🇸
Cambridge Medical Center, Cambridge, Minnesota, United States
🇺🇸Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸Essentia Health - Deer River Clinic, Deer River, Minnesota, United States
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 119
- Registration Number
- NCT02320058
- Locations
- 🇺🇸
UCLA Medical Hematology and Oncology, Los Angeles, California, United States
🇺🇸Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.